HIGHLIGHTS
- who: Luisa Klotz from the Department of, University Hospital Münster, Albert-Schweitzer-Campus, building, Münster, Germany have published the paper: Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor), in the Journal: (JOURNAL)
- what: The aim of the open , prospective, monocentric trial in patients with RRMS is therefore to improve the understanding of drug-induced changes in immune cell migration and immune cell function and its consequences on anti-viral immunity and to monitor its impact on clinical and paraclinical disease . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.